CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma

Table 2 Efficacy according to CRAFITY score, n (%)

	All (n = 192)	CRAFITY-high (n = 40)	CRAFITY-intermediate (n = 102)	CRAFITY-low (n = 50)	P value
PFS, months (95%CI)	5.2 (4.1-6.2)	3.1 (2.7-4.1)	6.0 (4.3-6.8)	8.4 (5.2-11.7)	< 0.0001
OS, months (95%CI)	17.7 (15.8-26.3)	6.6 (4.1-NR)	19.2 (15.8-26.8)	33.4 (21.4-NR)	< 0.0001
Initial response					0.0277
CR	3 (1.5)	0 (0.0)	2 (2.0)	1 (2.0)
PR	30 (15.6)	2 (5.0)	18 (17.6)	10 (20.0)
SD	105 (54.7)	18 (45.0)	58 (56.9)	29 (58.0)
PD	54 (28.1)	20 (50.0)	24 (23.5)	10 (20.0)
ORR	33 (17.1)	2 (5.0)	20 (19.6)	11 (22.0)	0.0669
DCR	138 (71.9)	20 (50.0)	78 (76.5)	40 (80.0)	0.0023

PFS: Progression-free survival; OS: Overall survival; CI: Confidence interval; NR: Not reach; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.